Veloxis Pharmaceuticals A/S Sustainability Profile
Veloxis Pharmaceuticals A/S, headquartered in Denmark (DK), is a prominent player in the biopharmaceutical industry, specialising in the development of innovative therapies for transplant patients. Founded in 2013, the company has made significant strides in enhancing patient outcomes through its unique formulations and targeted drug delivery systems. With a focus on immunosuppressive therapies, Veloxis is best known for its flagship product, Envarsus XR, which offers a once-daily dosing regimen that improves adherence and reduces side effects compared to traditional treatments. The company operates primarily in Europe and North America, positioning itself as a leader in the transplant market. Veloxis Pharmaceuticals has achieved notable milestones, including successful clinical trials and regulatory approvals, solidifying its reputation for excellence in patient care and commitment to advancing transplant medicine.
DitchCarbon Score
How does Veloxis Pharmaceuticals A/S's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Veloxis Pharmaceuticals A/S's score of 72 is higher than 83% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Veloxis Pharmaceuticals A/S, headquartered in Denmark (DK), currently does not report specific carbon emissions data, as indicated by the absence of emissions figures. The company is a current subsidiary of Asahi Kasei Corporation, which may influence its climate commitments and reporting practices. As part of its corporate family relationship, Veloxis Pharmaceuticals A/S inherits climate performance data from Asahi Kasei Corporation, which operates at a cascade level of 2. However, specific reduction targets or initiatives from Veloxis Pharmaceuticals A/S are not detailed in the available information. The absence of documented reduction targets or climate pledges suggests that Veloxis Pharmaceuticals A/S may still be in the process of establishing its own specific climate commitments. In the broader context of the pharmaceutical industry, companies are increasingly focusing on sustainability and carbon reduction strategies, often aligning with global initiatives such as the Science Based Targets initiative (SBTi) and the Carbon Disclosure Project (CDP). In summary, while Veloxis Pharmaceuticals A/S does not currently provide specific emissions data or reduction targets, its affiliation with Asahi Kasei Corporation may play a role in shaping its future climate commitments and sustainability strategies.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | - | 0,000,000,000 | - | - | - | - | - | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 |
| Scope 2 | - | 0,000,000,000 | - | - | - | - | - | 0,000,000,000 | 000,000,000 | 0,000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | - | - | 0,000,000,000 | 0,000,000,000 | 00,000,000,000 | 00,000,000,000 | 00,000,000,000 | 00,000,000,000 | 00,000,000,000 | 00,000,000,000 | 00,000,000,000 | 00,000,000,000 |
How Carbon Intensive is Veloxis Pharmaceuticals A/S's Industry?
How Carbon Intensive is Veloxis Pharmaceuticals A/S's Location?
Veloxis Pharmaceuticals A/S's Scope 3 Categories Breakdown
Veloxis Pharmaceuticals A/S's Scope 3 emissions, which decreased by 0% last year and increased by approximately 113% since 2015, demonstrating supply chain emissions tracking. Most of their carbon footprint comes from suppliers and value chain emissions, with Scope 3 emissions accounting for 79% of total emissions under the GHG Protocol, with "End-of-Life Treatment of Sold Products" being the largest emissions source at 41% of Scope 3 emissions.
Top Scope 3 Categories
Veloxis Pharmaceuticals A/S's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Veloxis Pharmaceuticals A/S has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
